![]() Apart from oncology, autoimmune disorders are the most popular in fact, close to 17% of product candidates in the pipeline are being developed for such conditions. Currently, almost 40% of the products in the development pipeline are focused on oncological indications, including hematological cancers and solid tumors.Examples include (in alphabetical order) Cancer Research UK, Chonnam National University, Dartmouth-Hitchcock Medical Center, Harlev Hospital, Memorial Sloan Kettering Cancer Center (MSKCC), National Cancer Institute (NCI) and University of Leeds. Several universities / research organizations, either independently or in collaboration with industry players, have also contributed to the development.In addition, small companies, such as (in alphabetical order) Affibody, Affilogic, Bicycle Therapeutics, Complix, Glythera, Navigo Proteins, Nordic Nanovector and Poseida Therapeutics, are also actively involved in this domain. Mid-sized companies that are actively contributing to the development of novel non-antibody scaffold based products include (in alphabetical order) Avacta, ITM Isotopen Technologien München, Molecular Partners, Pieris Pharmaceuticals and ThromboGenics. Some of the prominent large-sized companies engaged in this domain include (in alphabetical order) Allergan, AstraZeneca, BMS, GSK, Merck, Roche, Sanofi, Servier and Shire. The market landscape is well distributed across large-sized (21), mid-sized (5) and small-sized companies (8).Specifically, six products are in clinical evaluation (phase I/II and above) these are (in alphabetical order) abicipar pegol (Allergan and Molecular Partners), RG6206 (BMS and Roche), ABY-025 (Affibody), ABY-035 (Affibody), MP0250 (Molecular Partners), PRS-080 (Pieris Pharmaceuticals). A significant proportion (82%) of these candidates are in preclinical / discovery stages. Around 80 product candidates (drugs / diagnostics) based on non-antibody protein scaffolds are currently under various stages of development for a diverse range of indications.Notable examples include (in alphabetical order)Affibody® (Affibody), Affimer® (Avacta), Anticalin® (Pieris Pharmaceuticals), Adnectin TM (BMS), Bicycles® (Bicycle Therapeutics), DARPin® (Molecular Partners), Kunitz Domain (Shire) and Nanofitin® (Affilogic). Over 25 unique non-antibody protein scaffolds have been developed for the generation of different product candidates.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |